Craniotomy Surgery

4

Review clinical trials related to Craniotomy Surgery. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Pain Control and Quality of Recovery After Intravenous Methadone Versus Intravenous Remifentanil in Craniotomy Surgery

Postoperative pain is prevalent after intracranial surgery. Patients undergoing craniotomy are typically managed with short acting opioids to enable early and reliable post-operative neurological exam as well as avoid the risk of respiratory depression. However, a plethora of studies have shown that a majority of these patients experience moderate to severe pain in first 48 hours after surgery. Suboptimal pain control can lead to complications such as arterial hypertension and post-operative intracranial hemorrhage, and hence, increased morbidity and mortality. Intravenous (IV) methadone has a long analgesic half-life and has N-methyl-D-aspartate (NMDA) receptor antagonist and serotonin and norepinephrine reuptake inhibitor (SNRI) properties. It has previously been shown to reduce postoperative opioid requirements, postoperative nausea and vomiting (PONV), and postoperative pain scores in patients that underwent orthopedic, abdominal, complex spine, and cardiac surgery. Similar findings have been shown in obstetric patients that underwent caesarean delivery under general anesthesia as well as patients that underwent gynecologic surgery and received IV methadone intraoperatively. In a recently published retrospective study, a single intraoperative dose of IV methadone was well tolerated with lower pain scores as well as MME (oral morphine milligram equivalents) requirements for up to 72 hours after elective intracranial surgery. IV methadone has, however, never been compared with conventional management via IV remifentanil for functional recovery in patients undergoing elective intercranial surgery. The investigator's hypothesis is that intravenous (IV) methadone is non-inferior to IV remifentanil in patients who undergo elective intracranial surgery. It offers the advantage of being a single dose noninvasive analgesic modality that may contribute to decreasing MME consumption during the first 72 hours postoperatively, controlling postoperative pain, and improving quality of recovery after surgery.

Participants needed: 40
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: University of VirginiaUpdated: May 4, 2026Locations: 1
Eligibility criteria

Adult Patients between ages 18 and 65 years old. [+4]

Being unable or unwilling to sign a consent [+11]

Status: Not yet recruiting

Effects of Ultrasound-Guided Scalp Block on Opioid Use, Hemodynamics, and Postoperative Inflammation in Craniotomy

This study shows that in craniotomy patients using a skull pin head holder, an ultrasound-guided scalp block reduces perioperative opioid consumption, improves hemodynamic stability, and decreases the inflammatory response.

Participants needed: 60
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Fatih Sultan Mehmet Training and Research HospitalUpdated: Apr 22, 2026Locations: 1Duration: 1 Year
Eligibility criteria

Aged 18 years and older [+3]

Allergy to local anesthetics [+13]

Status: Not yet recruiting

Dexmedetomidine Versus Magnesium Sulfate Infusion in Craniotomy

To compare the intraoperative effects of Dexmedetomidine and Magnesium Sulfate infusion on intracranial pressure and cerebral perfusion pressure in adult patients undergoing craniotomy

Participants needed: 60
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: Assiut UniversityUpdated: Sep 30, 2025
Eligibility criteria

Age 18-65 years [+4]

Coagulopathy or current anticoagulation [+3]

Status: Not yet recruiting

When to Block? Timing of Scalp Block in Craniotomy

This study aims to evaluate the effect of scalp block timing-whether administered preoperatively or postoperatively-on postoperative recovery quality in patients undergoing craniotomy. The recovery quality will be assessed using the validated Quality of Recovery-40 (QoR-40) questionnaire. A total of 60 patients, aged 18-80 years, classified as ASA I-III and with a Glasgow Coma Scale (GCS) score of 15 upon admission to the recovery unit, will be enrolled. The primary outcome is the QoR-40 score. Secondary outcomes include hemodynamic changes and pain intensity measured by the Visual Analog Scale (VAS).

Participants needed: 60
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Sakarya UniversityUpdated: Jun 29, 2025Locations: 1
Eligibility criteria

Patients aged between 18 and 80 years. [+4]

Chronic use of analgesic medications prior to surgery. [+5]